Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chronic obstructive pulmonary disease. 5: systemic effects of COPD.

Literature DB >> 12454303

Chronic obstructive pulmonary disease. 5: systemic effects of COPD.

Abstract

The role of body cell mass wasting, muscle wasting, and changes in muscle metabolism in the pathogenesis of chronic obstructive pulmonary disease is reviewed.

Entities: Disease Gene

Mesh：

Substances：
Inflammation Mediators

Year: 2002 PMID： 12454303 PMCID： PMC1758796 DOI： 10.1136/thorax.57.12.1067

Source DB: PubMed Journal: Thorax ISSN： 0040-6376 Impact factor: 9.139

43 in total

Review 1. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy?

Authors: R T Jagoe; A L Goldberg
Journal: Curr Opin Clin Nutr Metab Care Date: 2001-05 Impact factor: 4.294

2. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).

Authors: A T Hill; E J Campbell; D L Bayley; S L Hill; R A Stockley
Journal: Am J Respir Crit Care Med Date: 1999-12 Impact factor: 21.405

Review 3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors: R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal: Am J Respir Crit Care Med Date: 2001-04 Impact factor: 21.405

4. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations.

Authors: M A Dentener; E C Creutzberg; A M Schols; A Mantovani; C van't Veer; W A Buurman; E F Wouters
Journal: Thorax Date: 2001-09 Impact factor: 9.139

5. Exercise-induced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease.

Authors: M P Engelen; A M Schols; J D Does; H R Gosker; N E Deutz; E F Wouters
Journal: Am J Respir Crit Care Med Date: 2000-11 Impact factor: 21.405

6. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease.

Authors: M Roland; A Bhowmik; R J Sapsford; T A Seemungal; D J Jeffries; T D Warner; J A Wedzicha
Journal: Thorax Date: 2001-01 Impact factor: 9.139

7. Effects of exercise on amino acid metabolism in patients with chronic obstructive pulmonary disease.

Authors: M P Engelen; E F Wouters; N E Deutz; J D Does; A M Schols
Journal: Am J Respir Crit Care Med Date: 2001-03 Impact factor: 21.405

8. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease.

Authors: R Casaburi; A Patessio; F Ioli; S Zanaboni; C F Donner; K Wasserman
Journal: Am Rev Respir Dis Date: 1991-01

9. Metabolic enzyme activity in the quadriceps femoris muscle in patients with severe chronic obstructive pulmonary disease.

Authors: P Jakobsson; L Jorfeldt; J Henriksson
Journal: Am J Respir Crit Care Med Date: 1995-02 Impact factor: 21.405

10. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease.

Authors: M Di Francia; D Barbier; J L Mege; J Orehek
Journal: Am J Respir Crit Care Med Date: 1994-11 Impact factor: 21.405

41 in total

Review 1. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues.

Authors: Maureen P M H Rutten-van Mölken; Lucas M A Goossens
Journal: Pharmacoeconomics Date: 2012-04 Impact factor: 4.981

2. Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link?

Authors: D D Sin; S F P Man
Journal: Thorax Date: 2006-01 Impact factor: 9.139

3. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease.

Authors: S F P Man; J E Connett; N R Anthonisen; R A Wise; D P Tashkin; D D Sin
Journal: Thorax Date: 2006-05-31 Impact factor: 9.139

4. Plasma inflammatory mediators associated with bone metabolism in COPD.

Authors: Jessica M Bon; Yingze Zhang; Steven R Duncan; Joseph M Pilewski; Diana Zaldonis; Adriana Zeevi; Kenneth R McCurry; Susan L Greenspan; Frank C Sciurba
Journal: COPD Date: 2010-06 Impact factor: 2.409

5. Role of increased CD8/CD28(null) T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease.

Authors: G Hodge; V Mukaro; P N Reynolds; S Hodge
Journal: Clin Exp Immunol Date: 2011-10 Impact factor: 4.330

6. Fat-free mass depletion in patients with COPD in Brazil: development of a new cutoff point and its relation with mortality and extrapulmonary manifestations.

Authors: A Travassos; A Rodrigues; K C Furlanetto; L Donária; G W Bisca; A G Nellessen; F Pitta; N A Hernandes
Journal: Eur J Clin Nutr Date: 2017-07-19 Impact factor: 4.016

7. Reproducibility of NIRS assessment of muscle oxidative capacity in smokers with and without COPD.

Authors: Alessandra Adami; Robert Cao; Janos Porszasz; Richard Casaburi; Harry B Rossiter
Journal: Respir Physiol Neurobiol Date: 2016-09-19 Impact factor: 1.931

8. Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial.

Authors: Carel R van Wetering; Floortje E van Nooten; Stijn J M Mol; Martine Hoogendoorn; Maureen P M H Rutten-Van Mölken; Annemie M Schols
Journal: Int J Chron Obstruct Pulmon Dis Date: 2008

Review 9. ABCD of the phosphodiesterase family: interaction and differential activity in COPD.

Authors: David M G Halpin
Journal: Int J Chron Obstruct Pulmon Dis Date: 2008

10. The relationship between adipokines, body composition, and bone density in men with chronic obstructive pulmonary disease.

Authors: Sheryl F Vondracek; Norbert F Voelkel; Michael T McDermott; Connie Valdez
Journal: Int J Chron Obstruct Pulmon Dis Date: 2009-07-20